Global kidney function tests market is expected to exhibit lucrative growth over the forecast period owing to increasing prevalence of chronic kidney disorders. Rising geriatric population which is more prone towards chronic ailments associated with vital organs is anticipated to upsurge market growth.
Other major factors that are expected to drive growth are high prevalence of obesity, hypertension, coronary diseases and renal fibrosis. Demand for kidney function test is mainly driven by increasing incidences and prevalence of diabetes. Other chronic diseases include human papilloma virus infections which are more common in females and affect kidney function by altering filtration, reabsorption, and secretion rate of renal system. Altered rates can be diagnosed by use of kidney function tests thus leading to growth in this market over the forecast period.
However, stringent regulatory approval procedures and growing attempts by regulatory authorities to check healthcare related expenses through development of compliant diagnostic products are some market-restraining factors that can impede growth of the kidney function tests market in the coming seven years.
Kidney function tests market is segmented on the basis of product types into different categories. These categories include clearance tests, dilution & concentration tests, urine tests, and visual imaging tests. Urine tests are further categorized into microalbuminuria, urine protein and urinanalysis.
Clearance tests provide assessment of filtration rate of glomerulus. Concentration tests involve determination of concentration of numerous substances in urine, including phosphate, glucose, amino acids, potassium, and sodium in order to aid in detection of kidney function impairment involved with their reabsorption properties.
Concentration tests segment held the largest market share in 2014 owing to applicability of these products in determination of pharmacokinetic properties of drugs and metabolizing power of liver and other associated organs.
According to the WHO estimates, more than 1.4 million people worldwide undergo renal replacement therapy every year which results into considerable increase in the incidence rate of chronic kidney disease. Such large pool of patients enhances need for development of improved and advanced techniques of diagnosis in order to curb the incidence rate thereby affecting market growth positively.
Development of novel drugs for chronic kidney ailments is also expected to raise demand of this market as these drugs are tested in-vivo in clinical phase of development. In-vivo determination of pharmacokinetic parameters such as renal clearance for novel drugs in order to determine half life is expected to fuel growth of this market growth over the forecast period.
Kidney imaging tests are also expected to register significant growth as these tests find applicability in kidney replacement surgeries to determine functioning level of kidney and also to evaluate amount of damage occurred to kidney.
Geographically, the kidney function tests market is segmented into North America, Asia Pacific, Latin America, Europe, and MEA. As of 2014, North America held the largest share in this market with respect to revenue as a consequence of propelling growth factors such as increased prevalence of chronic kidney ailments in this region, presence of government funding, and a considerably strong healthcare infrastructure.
Europe follows North America with respect to market share owing to presence of improving reimbursement policies in this region. Asia Pacific is expected to grow at a lucrative rate owing to higher incidence rate of chronic diseases such as diabetes and cardiovascular disorders which ultimately hamper kidney functioning and affect market growth. Furthermore, rising patient awareness and rising demand for advanced diagnostics and therapeutics regimens for chronic kidney diseases in the region.
Key players of this market include IC-Meditech, Inc., Metabolic Solutions Development Company, LLC, F. Hoffmann-La Roche Ltd, ManRos Therapeutics, Plexxikon Inc., Endocyte, Inc., Discovery Biomed, Inc., Kadmon Corporation, LLC, Baxter International Inc., Ipsen S.A., Otsuka Holdings Co., Ltd., Eli Lilly and Company, Galectin Therapeutics, Inc., and Pfizer Inc.
This market is highly competitive and mature. Market players are also involved in adopting competitive strategies such as expansion of the market in developing economies. These strategies include collaboration with diagnostic laboratories in order to maintain market share.
Companies are focusing on development of tests that can determine concentration of different molecular compounds and ions at the same time which can aid in tracking molecular abnormalities and ion imbalances during disease progression.
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.